Meeting
2017 ASCO Annual Meeting
Impact of early landmark responses with ponatinib on 4-yr outcomes in CP-CML patients (pts) in PACE, a pivotal phase II trial.
Authors
Martin Mueller
Universitätsmedizin Mannheim, Mannheim, Germany
Martin Mueller , Michele Baccarani , Michael W.N. Deininger , Francois Guilhot , Andreas Hochhaus , Timothy P. Hughes , Neil P. Shah , Moshe Talpaz , Stephanie Lustgarten , Sergio Santillana , Victor M Rivera , Timothy Piers Clackson , Jorge E. Cortes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Chronic Leukemia—CML
Clinical Trial Registration Number
NCT01207440
Citation
J Clin Oncol 35, 2017 (suppl; abstr 7050)
DOI
10.1200/JCO.2017.35.15_suppl.7050
Abstract #
7050
Poster Bd #
250
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
4-year results of the ponatinib phase II PACE trial in patients (pts) with heavily pretreated leukemia.
First Author: Jorge E. Cortes
Poster
2016 ASCO Annual Meeting
Impact of landmark responses on 3-year (yr) outcomes with ponatinib in heavily pretreated CP-CML patients (pts).
First Author: Martin C. Müller
Poster
2020 ASCO Virtual Scientific Program
An independent review of arterial occlusive events (AOEs) in the ponatinib (PON) phase II PACE trial (NCT01207440) in patients (pts) with Ph+ leukemia.
First Author: James L Januzzi
Poster
2019 ASCO Annual Meeting
Phase 3 PhALLCON study: Ponatinib (PON) versus imatinib (IM) with reduced-intensity chemotherapy (CT) in patients (pts) with newly diagnosed Philadelphia chromosome–positive (Ph+) ALL.
First Author: Elias Jabbour